Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by nine senior executives on November 11, 2013, at a price of 1,649.938 pence per share. Transactions included both personal contributions and matching company contributions under the ShareReward Plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of specific share purchase events.
Important Facts for Investors
- Transaction Date: November 11, 2013.
- Share Price: 1,649.938 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Type: Acquisitions via the ShareReward Plan (personal and matching elements).
- Disclosure Basis: Compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).